Article citationsMore>>

Chang, Y., Keramatnia, F., Ghate, P.S., Nishiguchi, G., Gao, Q., Iacobucci, I., et al. (2023) The Orally Bioavailable GSPT1/2 Degrader SJ6986 Exhibits in vivo Efficacy in Acute Lymphoblastic Leukemia. Blood, 142, 629-642.
https://doi.org/10.1182/blood.2022017813

has been cited by the following article:

• TITLE: The Role of GSPT2 in Tumor Cell Cycle Regulation: Mechanisms and Clinical Significance

  AUTHORS: Yu Cai, Yumei Wu

  KEYWORDS: GSPT2, Tumor, Biomarker, Cell Cycle, Signaling

  JOURNAL NAME: Journal of Cancer Therapy, Vol.16 No.1, January 13, 2025

  ABSTRACT: GSPT2 (G1 to S phase transition protein 2) has emerged as a critical regulator of the cell cycle and has garnered increased attention for its role in tumor biology in recent years. This review explores the multifaceted functions of GSPT2, highlighting its involvement in cell cycle regulation and signaling pathways, as well as its potential as a tumor biomarker. By analyzing the latest research findings, we examine the expression patterns of GSPT2 across various tumor types and its correlation with clinical outcomes, underscoring its significance in tumor initiation and progression. Furthermore, we discuss the prospects of GSPT2 as a therapeutic target, providing new insights for future research directions.